A mouse model for HIV-1 entry

John Pietzsch; Henning Gruell; Stylianos Bournazos; Bridget M. Donovan; Florian Klein; Ron Diskin; Michael S. Seaman; Pamela J. Bjorkman; Jeffrey V. Ravetch; Alexander Ploss; Michel C. Nussenzweig

doi:10.1073/pnas.1213409109

A mouse model for HIV-1 entry

John Pietzsch, Henning Gruell, Stylianos Bournazos, Bridget M. Donovan, Florian Klein, Ron Diskin, Michael S. Seaman, Pamela J. Bjorkman, Jeffrey V. Ravetch, Alexander Ploss, Michel C. Nussenzweig

Research output: Contribution to journal › Article › peer-review

66 Scopus citations

Abstract

Passive transfer of neutralizing antibodies against HIV-1 can prevent infection in macaques and seems to delay HIV-1 rebound in humans. Anti-HIV antibodies are therefore of great interest for vaccine design. However, the basis for their in vivo activity has been difficult to evaluate systematically because of a paucity of small animal models for HIV infection. Here we report a genetically humanized mouse model that incorporates a luciferase reporter for rapid quantitation of HIV entry. An antibody's ability to block viral entry in this in vivo model is a function of its bioavailability, direct neutralizing activity, and effector functions.

Original language	English (US)
Pages (from-to)	15859-15864
Number of pages	6
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	109
Issue number	39
DOIs	https://doi.org/10.1073/pnas.1213409109
State	Published - Sep 25 2012

All Science Journal Classification (ASJC) codes

General

Access to Document

10.1073/pnas.1213409109

Cite this

@article{cc8c349340ab4e8a84168695be0008f6,

title = "A mouse model for HIV-1 entry",

abstract = "Passive transfer of neutralizing antibodies against HIV-1 can prevent infection in macaques and seems to delay HIV-1 rebound in humans. Anti-HIV antibodies are therefore of great interest for vaccine design. However, the basis for their in vivo activity has been difficult to evaluate systematically because of a paucity of small animal models for HIV infection. Here we report a genetically humanized mouse model that incorporates a luciferase reporter for rapid quantitation of HIV entry. An antibody's ability to block viral entry in this in vivo model is a function of its bioavailability, direct neutralizing activity, and effector functions.",

author = "John Pietzsch and Henning Gruell and Stylianos Bournazos and Donovan, {Bridget M.} and Florian Klein and Ron Diskin and Seaman, {Michael S.} and Bjorkman, {Pamela J.} and Ravetch, {Jeffrey V.} and Alexander Ploss and Nussenzweig, {Michel C.}",

year = "2012",

month = sep,

day = "25",

doi = "10.1073/pnas.1213409109",

language = "English (US)",

volume = "109",

pages = "15859--15864",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "39",

}

TY - JOUR

T1 - A mouse model for HIV-1 entry

AU - Pietzsch, John

AU - Gruell, Henning

AU - Bournazos, Stylianos

AU - Donovan, Bridget M.

AU - Klein, Florian

AU - Diskin, Ron

AU - Seaman, Michael S.

AU - Bjorkman, Pamela J.

AU - Ravetch, Jeffrey V.

AU - Ploss, Alexander

AU - Nussenzweig, Michel C.

PY - 2012/9/25

Y1 - 2012/9/25

N2 - Passive transfer of neutralizing antibodies against HIV-1 can prevent infection in macaques and seems to delay HIV-1 rebound in humans. Anti-HIV antibodies are therefore of great interest for vaccine design. However, the basis for their in vivo activity has been difficult to evaluate systematically because of a paucity of small animal models for HIV infection. Here we report a genetically humanized mouse model that incorporates a luciferase reporter for rapid quantitation of HIV entry. An antibody's ability to block viral entry in this in vivo model is a function of its bioavailability, direct neutralizing activity, and effector functions.

AB - Passive transfer of neutralizing antibodies against HIV-1 can prevent infection in macaques and seems to delay HIV-1 rebound in humans. Anti-HIV antibodies are therefore of great interest for vaccine design. However, the basis for their in vivo activity has been difficult to evaluate systematically because of a paucity of small animal models for HIV infection. Here we report a genetically humanized mouse model that incorporates a luciferase reporter for rapid quantitation of HIV entry. An antibody's ability to block viral entry in this in vivo model is a function of its bioavailability, direct neutralizing activity, and effector functions.

UR - http://www.scopus.com/inward/record.url?scp=84866843530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866843530&partnerID=8YFLogxK

U2 - 10.1073/pnas.1213409109

DO - 10.1073/pnas.1213409109

M3 - Article

C2 - 23019371

AN - SCOPUS:84866843530

SN - 0027-8424

VL - 109

SP - 15859

EP - 15864

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 39

ER -

A mouse model for HIV-1 entry

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this